Why the study?
Combined dyslipidemia of overweight/obesity is prevalent in youth and associated with increased risk of early cardiovascular disease, but the impact and safety of statin therapy in adolescents were unknown.
Does pitavastatin calcium improve change in carotid-femoral pulse wave velocity in adolescents with overweight and obesity and combined dyslipidemia?
Does pitavastatin calcium improve change in carotid-femoral pulse wave velocity in adolescents with overweight and obesity and combined dyslipidemia?
In adolescents with combined dyslipidemia of overweight/obesity, 2 years of pitavastatin therapy safely lowered LDL-C but did not improve vascular stiffness as measured by pulse wave velocity.
Answers are grounded in this paper and cite their sources.
Does not support statins to improve vascular function in adolescent CDO; leaves open impact on long-term CV outcomes.
ABSTRACT Background Combined dyslipidemia of overweight/obesity (CDO) is prevalent in youth and is associated with an increased risk of early cardiovascular disease. Objective We sought to determine the impact and safety of statin therapy for CDO in adolescents. Methods A double-blind, randomized trial was performed across 18 North American sites. Participants ages 10-19 years with body mass index (BMI) >85th %ile and CDO defined as non-high density lipoprotein cholesterol (HDL-C) >120 mg/dL (3.10 mmol/L) and either low HDL-C or high triglyceride (TG):HDL-C ratio were randomized centrally to receive either pitavastatin calcium 4 mg/day or placebo for 2 years. The primary outcome was change in carotid-femoral pulse wave velocity (PWV), assessed at baseline, 6, 12, 18, and 24 months. Secondary outcomes included safety and lipid measures. Results The intention to treat analysis included 59 participants (33 males) who received pitavastatin calcium and 60 placebo (32 males) enrolled from June 2018 to April 2021. There were no significant changes or trends for PWV in either group. Compared to placebo, at 24 months pitavastatin was associated with significantly reduced low density lipoprotein cholesterol (LDL-C) (from 134+23 mg/dL [3.47+0.60 mmol/L] to 105+25 mg/dL [2.72+0.65] pitavastatin versus 130+25 mg/dL [3.37+0.65] to 126+27 mg/dL [3.26+0.70] placebo; p<0.001). There was one serious adverse event (placebo), and no significant differences in liver enzymes, muscle toxicity, glucose homeostasis, or linear growth. Conclusions Over 2 years, treatment with pitavastatin calcium of CDO for adolescents resulted in no changes in vascular measures. Statin therapy safely lowered atherogenic lipid particles, potentially reducing cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
McCrindle et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: